The overall aim of the group is to search for metabolomic biomarkers, either individually or in combined profiles, of disease for early detection, new subgroups, patient stratification, prognosis and prediction of response to therapy. To achieve this, the group has developed proprietary analytical tools that allow it to address a wide range of biomedical problems.

The group has a joint publication record (55 publications in 10 years) and has had its own uninterrupted public funding since 2007 (>1.6 million euros).

It has achieved a cumulative impact factor of 185 for its publications over the last 7 years. It also receives more than 150 citations per year. It has participated and participates in 5 European projects (eTUMOUR, HEALTHAGENTES, FRAILOMICS, EUMASCARA and GUTMOM). The group's work has been published during this period in prestigious specialised journals (Gut, Hepatology, International Journal of Epidemiology, Journal of the American College of Cardiology, Journal of Proteome Research and Cancer Research, among others).

The progressive incorporation of researchers to the group over the last 7 years has allowed it to increase its capacities and solve new problems, obtaining high quality research results. The translation of research results to clinical practice is achieved through established collaborations and the experience of more than 10 years of joint work with clinical groups at the Hospital Clínico de Valencia.

Since its creation in 2007, the group has characterised more than 12,000 biomedical samples of different nature (serum, plasma, urine, biopsies, tears, saliva, faecal extracts, culture medium, cells, etc.) for more than 30 national and international collaborations. The principal investigator has more than 22 years of experience (h-index 25) in the area of biomedical applications of NMR, has been invited to give numerous lectures on the subject, including the plenary Keynote Lecture at the recent congress of the European Society of Hypertension (ESH2017, Milan, >4500 participants; Gut microbiota and cardiovascular risk). He has also been scientific manager of a European project with 21 institutions and a budget of 7.5 million euros.

His research has been recognised with several awards and recognitions, including the Certificate of Merit of the European Society for Magnetic Resonance in Medicine and Biology; and the I3 Certification for outstanding scientific career from the MICINN.

Collaborators:

• María Martín Grau - Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana.
• Mercedes Pardo Tendero - Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana.
• Antonio Pellín Carcelén - Universitat de València.
• Itziar Pérez Terol - Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana.

Other human health activities